Section 232 Pharma in 2026: Keep July Section 301 Changes Separate
Scheduled Brazil and forced-labor pharmaceutical amendments are Section 301 changes, not proof of one general Section 232 pharma rate.
No universal current U.S. tariff rate is available from country of origin alone.
Classification, product scope, origin, entry time, MFN treatment, Section 232 status, and exemptions can change the result. When any required selector is missing, the safe output is indeterminate / review required.
What the reviewed sources support
- The scheduled July 31 pharmaceutical schedule changes belong to the Brazil and forced-labor Section 301 actions.
- They do not establish one general Section 232 pharmaceutical rate and must not be represented that way.
- Product classification, schedule coverage, entry time, and exceptions must be verified before any numeric result.
What to do before pricing or filing
- Confirm the complete HTS classification and the product description used for entry.
- Check the current HTSUS and controlling Chapter 99 notes for the entry date.
- Evaluate product schedules, transition rules, Section 232 interaction, and exclusions.
- Keep the result in review-required state until every selector and source is resolved.
The Attahir Labs rate table and TariffShield use fail-closed containment while the legacy country snapshots lack current row-level provenance. They must not supply a current numeric customs result.
Reviewed official sources
- USTR — final Brazil Section 301 action
- USTR — final forced-labor Section 301 action
- USTR — final-action prepublication notice
- USITC — current Harmonized Tariff Schedule
- CBP — determining duty rates
Checked through: July 25, 2026 at 22:30 UTC. Re-review required no later than July 28, 2026 at 04:01 UTC or sooner if an official source changes.
Disclaimer: Informational content only. Verify the current HTSUS and CBP instructions or use a licensed customs broker for an entry-specific decision.